
51 - 200 employees
Founded 2019
đ§Ź Biotechnology
đ Pharmaceuticals
đŹ Science
đ° $85M Series B on 2022-01
Biotechnology ⢠Pharmaceuticals ⢠Science
Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. The company is pioneering CAR T-cell therapies, leveraging the transformational power of T cells to potentially provide sustained, treatment-free remission for autoimmune conditions. Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through clinical trials targeting various autoimmune diseases, including multiple sclerosis, myasthenia gravis, systemic sclerosis, and lupus nephritis. Their pipeline features innovative chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats aimed at B cell-driven autoimmune diseases.
đ July 8
Improve your chances of getting an interview by checking your resume score before you apply.

51 - 200 employees
Founded 2019
đ§Ź Biotechnology
đ Pharmaceuticals
đŹ Science
đ° $85M Series B on 2022-01
Biotechnology ⢠Pharmaceuticals ⢠Science
Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. The company is pioneering CAR T-cell therapies, leveraging the transformational power of T cells to potentially provide sustained, treatment-free remission for autoimmune conditions. Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through clinical trials targeting various autoimmune diseases, including multiple sclerosis, myasthenia gravis, systemic sclerosis, and lupus nephritis. Their pipeline features innovative chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats aimed at B cell-driven autoimmune diseases.
⢠Provide strategic and operational regulatory leadership across Kyverna's cell therapy portfolio, with a focus on commercial readiness, labeling strategy, and health authority engagement. ⢠Define and execute global regulatory strategy to support clinical development, registration, and commercialization of Kyverna's autoimmune cell therapies. ⢠Translate scientific and clinical data into approvable, commercially viable labeling and lead interactions with regulatory authorities, including FDA and global counterparts. ⢠Lead global regulatory strategy for Kyverna's development programs, aligning clinical, CMC, and commercial objectives from early development through post-approval lifecycle management. ⢠Provide regulatory input to program governance, asset prioritization, and portfolio decisions, including scenario planning and risk mitigation. ⢠Anticipate and address regulatory challenges related to cell therapy development, manufacturing, comparability, and long-term follow-up. ⢠Serve as the primary senior regulatory interface with FDA, EMA, and other global health authorities. ⢠Lead and/or support key regulatory meetings, including INTERACT, pre-IND, End-of-Phase, pre-BLA/MAA, Advisory Committees, and post-marketing commitments. ⢠Drive regulatory negotiation strategy, including benefit-risk, endpoints, comparability, and post-approval requirements. ⢠Own and drive labeling strategy from early development through approval, ensuring labels support commercial differentiation, patient access, and lifecycle value. ⢠Lead development of Target Product Profiles (TPPs) and ensure alignment across Clinical, Regulatory, Commercial, and Market Access. ⢠Partner with Commercial, Medical Affairs, and Market Access to ensure regulatory decisions support launch readiness, promotional strategy, and payer engagement. ⢠Lead label negotiations with health authorities, balancing scientific evidence, regulatory expectations, and commercial objectives. ⢠Oversee and contribute to the preparation, review, and submission of INDs, CTAs, BLAs/MAAs, briefing packages, orphan drug applications, and other regulatory filings. ⢠Ensure submissions are high-quality, compliant, and strategically positioned. ⢠Maintain oversight of submission timelines, dependencies, and risk management, providing clear communication to senior leadership. ⢠Act as a strategic partner to Clinical Development, CMC, Research, Commercial, Legal, BD, and Alliance Management teams. ⢠Provide regulatory due diligence and strategic input for business development, in-licensing, out-licensing, and partnership opportunities. ⢠Oversee regulatory activities performed by CROs, consultants, and partners, ensuring quality and strategic alignment. ⢠Lead, mentor, and scale a high-performing regulatory team, fostering accountability, development, and a culture of collaboration. ⢠Establish and maintain regulatory policies, procedures, and infrastructure to support a growing, late-stage organization. ⢠Stay current on US and global regulatory intelligence and communicate key implications to stakeholders.
⢠Bachelor's degree in a scientific discipline required; advanced degree preferred. ⢠15+ years of progressive regulatory affairs experience in pharmaceutical or biotechnology, with significant advanced therapy experience. ⢠Cell and/or gene therapy experience preferred; autoimmune disease experience highly preferred. ⢠Demonstrated success leading global regulatory strategies through late-stage development and/or approvals, ideally including BLA/MAA experience. ⢠Proven experience with labeling strategy development and negotiation, with strong understanding of commercialization impacts. ⢠Deep knowledge of FDA regulations, ICH guidelines, and global regulatory frameworks; EMA and ex-US experience preferred. ⢠Track record of effective engagement with FDA OTP and/or divisions overseeing autoimmune or immune-mediated diseases. ⢠Strong executive communication skills with the ability to influence senior leadership and Board-facing audiences. ⢠Demonstrated ability to lead and scale teams in a fast-paced, high-growth environment. Prior supervisory experience preferred. ⢠Strategic mindset with the ability to balance scientific rigor, regulatory compliance, and commercial impact.
⢠bonus ⢠benefits ⢠participation in the company's stock plan
Apply Nowđ July 8
Corporate Governance, Risk, and Compliance Analyst at Onebrief managing RMF, CMMC, and SOC 2 compliance. Collaborating with various teams to ensure adherence to federal and corporate regulations.
đşđ¸ United States â Remote
đľ $160k - $200k / year
đ° $21M Venture Round on 2022-10
â° Full Time
đ Senior
đ´ Lead
đ Compliance
đ July 8
Manager, Compliance supporting the Chief Compliance Officer in ensuring adherence to healthcare compliance standards. Develops initiatives, manages audits, and leads compliance investigations.
đ July 7
Vice President of Regulatory Affairs developing global strategies for innovative therapeutics and devices at Contraline. Leading regulatory processes from preclinical stages to commercialization as a senior regulatory leader.
đ July 7
Head of Risk & Compliance overseeing regulatory and fraud strategies at Collectors' service. Leading compliance programs and risk frameworks across multiple business units.
đşđ¸ United States â Remote
đľ $197.2k - $280.1k / year
â° Full Time
đ´ Lead
đ Compliance
đŚ H1B Visa Sponsor
đ July 6
Quality Systems & Regulatory Affairs leader at CEFALY Technology ensuring compliance and audit readiness across quality systems. Focus on QMS optimization and regulatory affairs for medical devices.
đşđ¸ United States â Remote
đľ $160k - $180k / year
đ° Private Equity Round on 2019-08
â° Full Time
đ´ Lead
đ Compliance